Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Europe wide suspension for Rosiglitazone

The NHS Central Alerting System has issued an alert advising that the European Committee on Medicinal Products for Human Use has recommended the suspension of the marketing authorisations for rosiglitazone (Avandia®, Avandamet®) across the European Union.

The full content of the alert will be available tomorrow but registered users and those who receive CAS alerts by email will be able to access the content now. The European Medicines Agency will also

Clinicians are advised to put in place a system to ensure that all patients are reviewed and changed to another suitable treatment in line with NICE recommendations. This could be at the next routine appointment, or sooner if this will reduce patient anxiety.

Patients are advised to continue with their treatment but should contact the healthcare professional supervising their diabetic treatment.

Action: Clinicians should be aware of this product withdrawal. Patients being prescribed rosiglitazone should be identified and contacted to discuss any necessary changes to treatment.

Update: The European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) websites both now contain infomation about the recommendation for the withdrawal.

Share 'Europe wide suspension for Rosiglitazone' on Email Share 'Europe wide suspension for Rosiglitazone' on Delicious Share 'Europe wide suspension for Rosiglitazone' on Digg Share 'Europe wide suspension for Rosiglitazone' on Facebook Share 'Europe wide suspension for Rosiglitazone' on Google+ Share 'Europe wide suspension for Rosiglitazone' on reddit Share 'Europe wide suspension for Rosiglitazone' on StumbleUpon Share 'Europe wide suspension for Rosiglitazone' on Twitter

atomic-wealth

One Comments to “Europe wide suspension for Rosiglitazone”

  1. [...] Se veía venir y al final se ha cumplido la amenaza. La EMA (Agencia Europea de Medicamentos) ha dictado sentencia y el veredicto es contrario a la rosiglitazona (Avandia, Avandiamet, Avaglim), que va a ser retirada del mercado. Se basan en el metanálisis publicado este año en el que se advertía de un aumento de riesgo de IAM en los tratados con rosiglitazona. La noticia ha corrido como la pólvora por la red, y podéis encontrar más información en El Comprimido, Hemos leído, Sala de lectura y Prescribing Advice for GP. [...]

    Pingback by Lecturas Para El Fin De Semana (4) « Docencia Calvià — September 23, 2010 #
    Reply

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,522 spam comments.

atomic-wealth
fond-illness
summer